DOCSLIB.ORG

Progestin-Only Systemic Hormone Therapy for Menopausal Hot Flashes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progestin-Only Systemic Hormone Therapy for Menopausal Hot Flashes EDITORIAL Progestin-only systemic hormone therapy for menopausal hot flashes Clinicians treating postmenopausal hot flashes often recommend “systemic estrogen treatment.” However, progestin-only therapy also can effectively treat hot flashes and is an option for women with a contraindication to estrogen therapy. Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School he field of menopause medi- women. In one study, 133 postmeno- in postmenopausal women with cine is dominated by studies pausal women with an average age an American Heart Association risk T documenting the effective- of 55 years and approximately 3 years score greater than 10% over 10 years.3 ness of systemic estrogen or estro- from their last menstrual period were Additional contraindications to sys- gen-progestin hormone therapy for randomly assigned to 12 weeks of temic estrogen include women with the treatment of hot flashes caused treatment with placebo or micronized cardiac disease who have a throm- by hypoestrogenism. The effective- progesterone 300 mg daily taken at bophilia, such as the Factor V Leiden ness of progestin-only systemic bedtime.1 Mean serum progesterone mutation.4 hormone therapy for the treatment levels were 0.28 ng/mL (0.89 nM) and For women who are at high risk of hot flashes is much less studied 27 ng/mL (86 nM) in the women taking for estrogen-induced cardiovascu- and seldom is utilized in clinical placebo and micronized progesterone, lar events, micronized progesterone practice. A small number of stud- respectively. Compared with placebo, may be a better option than systemic ies have reported that progestins, micronized progesterone reduced day- estrogen for treating hot flashes. including micronized progesterone, time and nighttime hot flash frequency Alternatively, in these women at risk medroxyprogesterone acetate, and and severity. In addition, compared of cardiovascular disease a selective norethindrone acetate, are effective with placebo, micronized progester- serotonin reuptake inhibitor, such as treatment for hot flashes. Proges- one improved the quality of sleep.1 escitalopram, 10 mg to 20 mg daily, tin-only systemic hormone therapy Most reviews conclude that may be a good option for treating might be especially helpful for post- micronized progesterone has mini- postmenopausal hot flashes.5 menopausal women with moderate mal cardiovascular risk.2 Micronized to severe hot flashes who have a con- progesterone therapy might be espe- traindication to estrogen treatment. cially helpful for postmenopausal Medroxyprogesterone women with moderate to severe hot acetate flashes who have a contraindication Medroxyprogesterone acetate, at a Micronized progesterone to estrogen treatment such as those at dosage of 20 mg daily, is an effective Micronized progesterone (Prome- increased risk for cardiovascular dis- treatment for hot flashes. In a ran- trium) 300 mg daily taken at bed- ease or women with a thrombophilia. domized clinical trial 27 postmeno- time has been reported to effectively Many experts believe that systemic pausal women with hot flashes were treat hot flashes in postmenopausal estrogen therapy is contraindicated randomly assigned to treatment with 6 OBG Management | February 2020 | Vol. 32 No. 2 mdedge.com/obgyn placebo or medroxyprogesterone group and 0 in both the LA plus NEA acetate 20 mg daily for 4 weeks. Vaso- 5 mg daily group and the LA plus NEA motor flushes were decreased by 26% 5 mg plus CEE 1.25 mg daily group. and 74% in the placebo and medroxy- This study demonstrates that NEA progesterone groups, respectively.6 5 mg daily is an effective treatment Depot medroxyprogesterone for hot flashes. acetate injections at dosages from In the same study, LA plus 150 mg to 400 mg also have been placebo was associated with a sig- reported to effectively treat hot nificant decrease in lumbar spine flashes.7,8 In a trial comparing the bone mineral density. No significant effectiveness of estrogen monother- decrease in bone mineral density was apy (conjugated equine estrogen 0.6 observed in the women who received mg daily) with progestin monotherapy LA plus NEA 5 mg daily. This finding (medroxyprogesterone acetate 10 mg indicates that NEA 5 mg reduces bone daily), both treatments were equally 2.16) compared with never users of absorption caused by hypoestrogen- effective in reducing hot flashes.9 postmenopausal hormone therapy. ism. In humans, norethindrone is a The E3N study indicates that micron- substrate for the aromatase enzyme ized progesterone may have a more system.14 Small quantities of ethinyl Micronized progesterone favorable breast health profile than estradiol may be formed by aroma- vs medroxyprogesterone medroxyprogesterone acetate.12 tization of norethindrone in vivo,15,16 acetate contributing to the effectiveness of Experts in menopause medicine NEA in suppressing hot flashes and have suggested that in postmeno- Norethindrone acetate preserving bone density. pausal women micronized pro- Norethindrone acetate monotherapy gesterone has a better pattern of is not commonly prescribed for the benefits and fewer risks than med- treatment of menopausal hot flashes. Progestin: The estrogen roxyprogesterone acetate.10,11 For However, a large clinical trial has dem- alternative to hot flashes example, in the E3N observational onstrated that norethindrone acetate For postmenopausal women with study of hormones and breast can- effectively suppresses hot flashes in moderate to severe hot flashes, estro- cer risk, among 80,377 French post- women with endometriosis treated gen treatment reliably suppresses hot menopausal women followed for with depot leuprolide acetate (LA). flashes and often improves sleep qual- a mean of 8 years, the combina- In one trial 201 women with endome- ity and mood. For postmenopausal tion of transdermal estradiol plus triosis were randomly assigned to 12 women with a contraindication to oral micronized progesterone was months of treatment with13: estrogen treatment, progestin-only associated with no significantly • LA plus placebo pills treatment with micronized progester- increased risk of breast cancer (rela- • LA plus norethindrone acetate one or norethindrone acetate may be tive risk [RR], 1.08, 95% confidence (NEA) 5 mg daily an effective option. interval [CI], 0.89–1.31) compared • LA plus NEA 5 mg daily plus conju- with never users of postmenopausal gated equine estrogen (CEE) 0.625 hormone therapy.12 By contrast, the mg daily, or combination of oral estrogen plus • LA plus NEA 5 mg daily plus CEE [email protected] medroxyprogesterone acetate was 1.25 mg daily. associated with an increased risk of The median number of hot flashes in Dr. Barbieri reports no financial rela- breast cancer (RR, 1.48; 95% CI, 1.02– 24 hours was 6 in the LA plus placebo tionships relevant to this article. References 1. Hitchcock CL, Prior JC. Oral micronized proges- one use by midlife menopausal women. Maturitas decision making: a clinical decision-suport tool terone for vasomotor symptoms—a placebo- 2012; 72: 192-202. from The North American Menopause Society. controlled randomized trial in healthy postmeno- 3. Manson JE, Ames JM, Shapiro M, et al. Algorithm Menopause. 2015;22:247-253. pausal women. Menopause. 2012;19:886-893. and mobile app for menopausal symptom man- 4. Herrington DM, Vittinghoff E, Howard TD, et al. DIGITAL ILLUSTRATION: JOHN J. DENAPOLI IMAGES: © ANA BLAZIC PAVLOVIC/VADYM NECHYPORENKO/SHUTTERSTOCK JOHN J. DENAPOLI IMAGES: © ANA BLAZIC PAVLOVIC/VADYM ILLUSTRATION: DIGITAL 2. Spark MJ, Willis J. Systematic review of progester- agement and hormonal/nonhormonal therapy Factor V Leiden, hormone replacement therapy, CONTINUED ON PAGE 8 mdedge.com/obgyn Vol. 32 No. 2 | February 2020 | OBG Management 7 EDITORIAL CONTINUED FROM PAGE 7 and risk of venous thromboembolic events North Central Cancer Treatment Group Trial 13. Hornstein MD, Surrey ES, Weisberg GW, et in women with coronary disease. Arterioscler N99C7. J Clin Oncol. 2006;24:1409-1414. al. Leuprolide acetate depot and hormonal Thromb Vasc Biol. 2002;22:1012-1017. 9. Prior JC, Nielsen JD, Hitchcock CL, et al. Med- add-back in endometriosis: a 12-month study. 5. Ensrud KE, Joffe H, Guthrie KA, et al. Effect of roxyprogesterone and conjugated oestrogen are Lupron Add-Back Study Group. Obstet Gynecol. escitalopram on insomnia symptoms and sub- equivalent for hot flushes: 1-year randomized 1998;91:16-24. jective sleep quality in healthy perimenopausal double-blind trial following premenopausal ova- 14. Barbieri RL, Canick JA, Ryan KJ. High-affinity ste- and postmenopausal women with hot flashes: riectomy. Clin Sci (Lond). 2007;112:517-525. roid binding to rat testis 17 alpha-hydroxylase and a randomized controlled trial. Menopause. 10. L’hermite M, Simoncini T, Fuller S, et al. Could trans- human placental aromatase. J Steroid Biochem. 2012;19:848-855. dermal estradiol + progesterone be a safer postmen- 1981;14:387-393. 6. Schiff I, Tulchinsky D, Cramer D, et al. Oral medroxy- opausal HRT? A review. Maturitas. 2008;60:185-201. 15. Chu MC, Zhang X, Gentzschein E, et al. Forma- progesterone in the treatment of postmenopausal 11. Simon JA. What if the Women’s Health Initiative tion of ethinyl estradiol in women during treat- symptoms. JAMA. 1980;244:1443-1445. had used transdermal estradiol and oral proge- ment with norethindrone acetate. J Clin Endocri- 7. Bullock JL, Massey FM, Gambrell RD Jr. Use of sterone instead? Menopause. 2014;21:769-783. nol Metab. 2007;92:2205-2207. medroxyprogesterone acetate to prevent meno- 12. Fournier A, Berrino F, Clavel-Chapelon F. Unequal 16. Chwalisz K, Surrey E, Stanczyk FZ. The hormonal pausal symptoms. Obstet Gynecol. 1975;46:165-168. risks for breast cancer associated with different profile of norethindrone acetate: rationale for 8. Loprinzi CL, Levitt R, Barton D, et al. Phase III hormone replacement therapies: results from add-back therapy with gonadotropin-releasing comparison of depot medroxyprogesterone the E3N cohort study. Breast Cancer Res Treat. hormone agonists in women with endometriosis.
Load more

Recommended publications
  • Informed Consent for Feminizing Hormone Therapy
    Informed Consent for Feminizing Hormone Therapy For _________________________ Date of Birth: _____________ Name Used: ____________________ Patient Name as listed in chart Name if different from chart This form will assist you (and your guardian) to think through the expected effects of hormone therapy including possible unwanted side effects. You are encouraged to talk about this treatment with your medical provider and decide if hormone therapy is right for you (your child). By signing this form, you are stating that you have discussed the effects and risks of this medication with your medical provider or a member of the medical team and that you understand and accept these effects and possible risks. You (and your guardian) may ask questions and talk about any concerns you have related to this treatment at any time in this process. Estrogen (usually estradiol) is used to feminize the body (make it look more traditionally female). This medical treatment will reduce some male features and increase some female features of the body. Androgen (testosterone) blockers further decrease the amount of and/or block the effect of testosterone and masculinization of the body. Your medical provider will help decide which form and the amount of estrogen (shots, pills, gels, patches) and androgen blockers (pills, gels, shots, implanted) that are best for you based on your personal needs and any medical or mental health conditions you might have. Each person’s body responds to estrogen differently and it is hard to promise or predict with certainty how each person may respond to treatment. Your medical provider will talk with you throughout the treatment and will help you achieve the best results safely.
    [Show full text]
  • A Guide to Feminizing Hormones – Estrogen
    1 | Feminizing Hormones ​ ​ A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, ​ when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex ​ organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), ​ dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone ​ • Progestin: progesterone ​ Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body.
    [Show full text]
  • 6 Ways Your Brain Transforms During Menopause
    6 Ways Your Brain Transforms During Menopause By Aviva Patz Movies and TV shows have gotten a lot of laughs out of menopause, with its dramatic hot flashes and night sweats. But the midlife transition out of our reproductive years—marked by yo-yoing of hormones, mostly estrogen—is a serious quality-of-life issue for many women, and as we're now learning, may leave permanent marks on our health. "There is a critical window hypothesis in that what is done to treat the symptoms and risk factors during perimenopause predicts future health and symptoms," explains Diana Bitner, MD, assistant professor at Michigan State University College of Human Medicine and author of I Want to Age Like That: Healthy Aging Through Midlife and Menopause. "If women act on the mood changes in perimenopause and get healthy and take estrogen, the symptoms are much better immediately and also lifelong." (Going through menopause and your hormones are out of whack? Then check out The Hormone Reset Diet to balance your hormones and lose weight.) For many decades, the mantra has been that the only true menopausal symptoms are hot flashes and vaginal dryness. Certainly they're the easiest signs to spot! But we have estrogen receptors throughout the brain and body, so when estrogen levels change, we experience the repercussions all over—especially when it comes to how we think and feel. Two large studies, including one of the nation's longest longitudinal investigations, have revealed that there's a lot going on in the brain during this transition. "Before it was hard to tease out: How much of this is due to the ovaries aging and how much is due to the whole body aging?" says Pauline Maki, PhD, professor of psychiatry and psychology at the University of Illinois at Chicago and Immediate Past President of the North American Menopause Society (NAMS).
    [Show full text]
  • Exposure to Female Hormone Drugs During Pregnancy
    British Journal of Cancer (1999) 80(7), 1092–1097 © 1999 Cancer Research Campaign Article no. bjoc.1998.0469 Exposure to female hormone drugs during pregnancy: effect on malformations and cancer E Hemminki, M Gissler and H Toukomaa National Research and Development Centre for Welfare and Health, Health Services Research Unit, PO Box 220, 00531 Helsinki, Finland Summary This study aimed to investigate whether the use of female sex hormone drugs during pregnancy is a risk factor for subsequent breast and other oestrogen-dependent cancers among mothers and their children and for genital malformations in the children. A retrospective cohort of 2052 hormone-drug exposed mothers, 2038 control mothers and their 4130 infants was collected from maternity centres in Helsinki from 1954 to 1963. Cancer cases were searched for in national registers through record linkage. Exposures were examined by the type of the drug (oestrogen, progestin only) and by timing (early in pregnancy, only late in pregnancy). There were no statistically significant differences between the groups with regard to mothers’ cancer, either in total or in specified hormone-dependent cancers. The total number of malformations recorded, as well as malformations of the genitals in male infants, were higher among exposed children. The number of cancers among the offspring was small and none of the differences between groups were statistically significant. The study supports the hypothesis that oestrogen or progestin drug therapy during pregnancy causes malformations among children who were exposed in utero but does not support the hypothesis that it causes cancer later in life in the mother; the power to study cancers in offspring, however, was very low.
    [Show full text]
  • Menopausal Hormone Therapy
    GYNAECOLOGY ENDOCRINOLOGY Menopausal hormone therapy: where are we now? Menopausal hormone therapy (MHT) is an effective treatment for symptoms associated with menopause, such as hot flushes, night sweats, mood changes, sleep disturbances and changes in sexual function. While the evidence around MHT has changed over the years, there is now international consensus that the benefits of MHT are likely to outweigh the risks for most women aged < 60 years or within ten years of menopause, for whom menopausal symptoms are affecting their quality of life. KEY PRACTICE POINTS: Every woman’s experience of menopause is different, and Among the oestrogen and progestogen formulations perceptions of menopause vary across cultures. Most available, transdermal oestrogen (funded) and micronised women will experience some menopause symptoms, progesterone (not funded) are associated with the lowest however, only some will seek treatment. risk of adverse effects Menopausal hormone therapy (MHT) is likely to offer overall There is no specific recommended duration for MHT. The benefit to women with menopausal symptoms affecting decision to continue treatment should be reviewed on their quality of life if they are aged < 60 years or within ten an annual basis, taking into account any changes in the years of menopause patient’s risk factors, adverse effects and extent of benefit. Adverse outcomes associated with MHT include breast If women primarily seek assistance for urogenital symptoms cancer, stroke and venous thromboembolism (VTE). of menopause, vaginal products are recommended instead However, the risk of these outcomes depends on factors of MHT. This includes moisturisers, lubricants or a vaginal such as the age or time since menopause when MHT oestrogen cream or pessary.
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • EFFECTS of FEMINIZING HORMONE THERAPY (ESTROGEN) Effects in RED Are Permanent Changes
    EFFECTS OF FEMINIZING HORMONE THERAPY (ESTROGEN) Effects in RED are permanent changes. Effect First noticeable: Maximum effect: Breast enlargement 3-6 months 2-3 years Softening of skin, less 3-6 months Unknown oily skin Slower, thinner growth 6-12 months 3 years or more of facial and body hair Decrease in male Hair loss stops in 1-3 1-2 years pattern baldness months but hair does not grow back Decreased muscle mass 3-6 months 1-2 years / strength Body fat redistribution 3-6 months 2-5 years (more fat on buttocks, hips, thighs, face) Decreased libido (sex 1-3 months 1-2 years drive) Decreased spontaneous 1-3 months 3-6 months erections Decreased volume 3-6 months 2-3 years (shrinking) of the testes Decreased sperm Variable Variable production/Infertility What are the emotional and intellectual effects of estrogen? People are very different so their emotional and intellectual changes vary widely. People taking estrogen have reported: ● feeling more emotional and more in touch with their feelings ● crying more easily ● mood swings ● depression or sadness ● thinking differently, having different ways of looking at things ● feeling “more like myself” when taking a hormone that aligns with gender identity; feeling more comfortable in one’s body What estrogen does not do: ● change a person’s bone structure ● change a person’s height ● stop the growth of facial hair or eliminate a beard ● cause male pattern balding on the scalp to grow back ● raise the pitch of the voice to a higher level ● provide reliable birth control ● protect against sexually transmitted infections What are the risks of taking estrogen? The major risks are: ● blood clots ― can result in stroke or even death ● gallbladder disease ● liver disease ● weight gain ● high cholesterol which causes heart disease ● high blood pressure EFFECTS OF MASCULINIZING HORMONE THERAPY (TESTOSTERONE) Effects in RED are permanent changes.
    [Show full text]
  • Duloxetine and Escitalopram for Hot Flushes: Efficacy and Compliance in Breast Cancer Survivors
    Original Article Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors N. BIGLIA, MD, PHD, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, V.E. BOUNOUS, MD, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, T. SUSINI, MD, PHD, Breast Unit Department of Health Science, OB & GYN Section, AOU Careggi, School of Medicine, University of Florence, Florence, S. PECCHIO, MD, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, L.G. SGRO, MD, PHD, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, V. TUNINETTI, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, & R. TORTA, MD, PHD, Psycho-Oncology Unit, Department of Neurosciences, University of Turin, Turin, Italy BIGLIA N., BOUNOUS V.E., SUSINI T., PECCHIO S., SGRO L.G., TUNINETTI V. & TORTA R. (2016) Euro- pean Journal of Cancer Care Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors Selective serotonin reuptake inhibitors (SSRI) and serotonin–norepinephrine reuptake inhibitors (SNRI) might be an effective treatment for hot flushes (HFs) in breast cancer survivors (BCSs). This study aims to compare the efficacy and tolerability of duloxetine (SNRI) versus escitalopram (SSRI) in reducing frequency and severity of HFs in BCSs and to assess the effect on depression. Thirty-four symptomatic BCSs with emotional impairment received randomly duloxetine 60 mg daily or escitalopram 20 mg daily for 12 weeks. Patients were asked to record in a diary HF frequency and severity at baseline and after 4 and 12 weeks of treatment.
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrORILISSA® elagolix (as elagolix sodium) tablets 150 mg and 200 mg Gonadotropin releasing hormone (GnRH) receptor antagonist Date of Preparation: October 4, 2018 AbbVie Corporation Date of Revision: 8401 Trans-Canada Highway March 3, 2020 St-Laurent, Qc H4S 1Z1 Submission Control No: 233793 ORILISSA Product Monograph Page 1 of 40 Date of Revision: March 3, 2020 and Control No. 233793 RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 4 1. INDICATIONS ................................................................................................................ 4 1.1. Pediatrics (< 18 years of age): .................................................................................. 4 1.2. Geriatrics (> 65 years of age): .................................................................................. 4 2. CONTRAINDICATIONS ................................................................................................. 4 3. DOSAGE AND ADMINISTRATION ................................................................................ 5 3.1. Dosing Considerations ............................................................................................. 5 3.2. Recommended Dose and Dosage Adjustment ......................................................... 5 3.3. Administration .........................................................................................................
    [Show full text]
  • The Evaluation of Spells
    r e V i e W the evaluation of spells I.N. van Loon1*, J. Lamberts1, G.D. Valk2, A.F. Muller1 1Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands, 2Department of Internal Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands, *corresponding author: tel.: +31 (0)88- 25 05 901, e-mail: [email protected] a B s t r a C t the differential diagnosis of spells is broad and includes table 1. Differential diagnosis of episodic symptoms both innocent and life-threatening conditions with a endocrine pharmacological considerable overlap in clinical presentation. extensive Pheochromocytoma Abrupt withdrawal of adrener- diagnostic testing is often performed, without reaching a Thyreotoxicosis gic inhibitor final diagnosis, or resulting in false-positives. a thorough Hypogonadism (menopause) MAO inhibitor in combination Medullary thyroid carcinoma with specific food medical history, including family history and medication, Pancreatic islet cell tumours Sympathicomimetic and physical examination are required to obtain clues (e.g. insulinoma, VIPoma) Hallucinating drugs (cocaine, Gastroenteropancreatic LSD) about the cause of a spell. an overview of spells with their neuroendocrine Chlorpropamide-alcohol flush stereotypic phenotype in general internal medicine practice tumours (carcinoid syndrome) Vancomycin is presented in this article. Besides, a diagnostic approach Hypoglycaemia Calcium antagonist is proposed for the clinical evaluation of spells. Cardiovascular neurological Labile hypertension Autonomic neuropathy
    [Show full text]
  • Non-Hormonal Strategies for Managing Menopausal Symptoms in Cancer Survivors: an Update
    Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update Nicoletta Biglia1, Valentina E Bounous1, Francesco De Seta2, Stefano Lello3, Rossella E Nappi4 and Anna Maria Paoletti5 1Division of Gynecology and Obstetrics, Department of Surgical Sciences, School of Medicine, University of Torino, Largo Turati 62, 10128 Torino, Italy 2Institute for Maternal and Child Health-IRCCS ‘Burlo Garofolo’, University of Trieste, via dell’Istria 65/1, 34137 Trieste, Italy 3Department of Woman and Child Health, Policlinico Gemelli Foundation, Largo Gemelli 1, 00168 Rome, Italy 4Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S Matteo Foundation, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Viale Camillo Golgi 19, 27100 Pavia, Italy 5 Department of Obstetrics and Gynecology, Department of Surgical Sciences, University of Cagliari, University Hospital of Cagliari, SS 554 km 4,500, 09042 Monserrato, Italy Abstract Vasomotor symptoms, particularly hot flushes (HFs), are the most frequently reported symptom by menopausal women. In particular, for young women diagnosed with breast cancer, who experience premature ovarian failure due to cancer treatments, severe HFs are an unsolved problem that strongly impacts on quality of life. The optimal manage- ment of HFs requires a personalised approach to identify the treatment with the best Review benefit/risk profile for each woman. Hormonal replacement therapy (HRT) is effective in managing HFs but it is contraindicated in women with previous hormone-dependent cancer. Moreover, many healthy women are reluctant to take HRT and prefer to manage symptoms with non-hormonal strategies. In this narrative review, we provide an update on the current available non-oestrogenic strategies for HFs management for women who cannot, or do not wish to, take oestrogens.
    [Show full text]
  • Menopause & Hormones: Common Questions
    Menopause & Hormones Common Questions What is menopause? What is hormone therapy for menopause? Menopause is a normal, natural change in a woman’s Lower hormone levels in menopause may lead to hot life when her period stops. That’s why some people flashes, vaginal dryness, and thin bones. To help with call menopause “the change of life” or “the change.” these problems, women may be prescribed estrogen During menopause a woman’s body slowly produces or estrogen with progestin (another hormone). Like less of the hormones estrogen and progesterone. This all medicines, hormone therapy has benefits and often happens between ages 45 and 55. A woman has risks. Talk to your doctor, nurse, or pharmacist about reached menopause when she has not had a period for hormone therapy. If you decide to use hormone 12 months in a row. therapy, use it at the lowest dose that helps. Also use hormones for the shortest time that you need them. What are the symptoms of menopause? Who should not take hormone therapy for Every woman’s period will stop at menopause. Some menopause?Who should not take hormone therapy women may not have any other symptoms at all. As for menopause? you near menopause, you may have: WomenWomen who: who: • Changes in your period—time between periods or • • Think Think they they ar aree pregnant. pregnant. flow may be different. • • Have Have pr problemsoblems with with vaginal vaginal bleeding. bleeding. • Hot flashes (“hot flushes”)—getting warm in the • • Have Have had certain certain kinds kinds of ofcancers. cancers. face, neck, or chest, with and without sweating.
    [Show full text]